News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter

Cesca Therapeutics To Present At The Rodman & Renshaw 16th Annual Global Investment Conference

9/4/2014 9:03:34 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

RANCHO CORDOVA, Calif., Sept. 4, 2014 (GLOBE NEWSWIRE) -- Cesca Therapeutics Inc. (Nasdaq:KOOL), an autologous cell-based regenerative medicine company, today announced that Matthew Plavan, Chief Executive Officer of Cesca, will present at the Rodman & Renshaw® Annual Global Investment Conference, being held at the New York Palace Hotel in New York. The presentation will take place on Tuesday, September 9, 2014 at 1:40 PM Eastern Time.

The presentation will be webcast and available to the public online at A replay will be available for 90 days after the presentation.

About Cesca Therapeutics

Cesca Therapeutics Inc. ( is engaged in the research, development, and commercialization of autologous cell-based therapeutics for use in regenerative medicine. We are a leader in developing and manufacturing automated blood and bone marrow processing systems that enable the separation, processing and preservation of cell and tissue therapy products. These include:

  • SurgWerksPlatform, a proprietary stem cell therapy point-of-care kit system for treating vascular and orthopedic indications that integrate the following indication specific systems:

- Cell harvesting

- Cell processing and selection

- Cell diagnostics

- Cell delivery

  • AXP® AutoXpress® Platform (AXP), a proprietary family of automated devices that includes the AXP and the MXP® MarrowXpress® and companion sterile blood processing disposables for harvesting stem cells in closed systems. The AXP device is used for the processing of cord blood.
  • The MarrowXpress Platform (MXP), a derivative product of the AXP and its accompanying disposable bag set, isolates and concentrates stem cells from bone marrow. Self-powered and microprocessor-controlled, the MXP contains flow control optical sensors that volume-reduces blood from bone marrow to a user defined volume in 30 minutes, while retaining over 90% of the MNCs.
  • The Res-Q™ 60 (Res-Q), a point-of-care system designed for the preparation of cell concentrates, including stem cells, from bone marrow aspirates and whole blood for platelet rich plasma (PRP).
  • The BioArchive® System, an automated cryogenic device, used by cord blood stem cell banks in more than 30 countries for cryopreserving and archiving cord blood stem cell units for transplant.

Forward-Looking Statements

This press release contains forward-looking statements. Such forward-looking statements include but are not limited to that Cesca Therapeutics Inc. will provide unmatched world-class capability and service to its clients. These statements involve risks and uncertainties that could cause actual outcomes to differ materially from those contemplated by the forward-looking statements. A more complete description of risks that could cause actual events to differ from the outcomes predicted by our forward-looking statements is set forth under the caption "Risk Factors" in Cesca Therapeutics annual report on Form 10-K and other reports we file with the Securities and Exchange Commission from time to time, and you should consider each of those factors when evaluating the forward-looking statements.

CONTACT: Cesca Therapeutics Inc. Website: Investor Relations + 1-646-863-6519, or

Cesca Therapeutics Inc. logo

Help employers find you! Check out all the jobs and post your resume.

Read at

comments powered by Disqus